Teva Branded Pharmaceutical Products R&D LLC
Quick facts
Phase 3 pipeline
- TV-44749 · Pain Management
TV-44749 is a selective inhibitor of transient receptor potential vanilloid 1 (TRPV1) that reduces pain signaling by blocking capsaicin-sensitive nociceptors.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: